Logo image of AMPH

AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Fundamental Analysis

NASDAQ:AMPH - Nasdaq - US03209R1032 - Common Stock - Currency: USD

27.52  -0.91 (-3.2%)

After market: 27.52 0 (0%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to AMPH. AMPH was compared to 192 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. AMPH is cheap, but on the other hand it scores bad on growth. This makes AMPH very considerable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

AMPH had positive earnings in the past year.
In the past year AMPH had a positive cash flow from operations.
AMPH had positive earnings in 4 of the past 5 years.
Of the past 5 years AMPH 4 years had a positive operating cash flow.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

1.2 Ratios

With an excellent Return On Assets value of 10.21%, AMPH belongs to the best of the industry, outperforming 93.48% of the companies in the same industry.
AMPH's Return On Equity of 21.67% is amongst the best of the industry. AMPH outperforms 94.57% of its industry peers.
AMPH's Return On Invested Capital of 12.46% is amongst the best of the industry. AMPH outperforms 89.67% of its industry peers.
AMPH had an Average Return On Invested Capital over the past 3 years of 11.94%. This is significantly below the industry average of 44.16%.
The 3 year average ROIC (11.94%) for AMPH is below the current ROIC(12.46%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 10.21%
ROE 21.67%
ROIC 12.46%
ROA(3y)10.22%
ROA(5y)7.84%
ROE(3y)17.58%
ROE(5y)13.18%
ROIC(3y)11.94%
ROIC(5y)N/A
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 10 15 20

1.3 Margins

Looking at the Profit Margin, with a value of 21.80%, AMPH belongs to the top of the industry, outperforming 94.02% of the companies in the same industry.
AMPH's Profit Margin has improved in the last couple of years.
AMPH's Operating Margin of 29.61% is amongst the best of the industry. AMPH outperforms 93.48% of its industry peers.
AMPH's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 52.98%, AMPH is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
AMPH's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 29.61%
PM (TTM) 21.8%
GM 52.98%
OM growth 3Y114.39%
OM growth 5YN/A
PM growth 3Y276.41%
PM growth 5YN/A
GM growth 3Y10.26%
GM growth 5Y8.62%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 20 30 40 50

More info and screens

6

2. Health

2.1 Basic Checks

AMPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
There is no outstanding debt for AMPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 2.71 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
AMPH's Altman-Z score of 2.71 is fine compared to the rest of the industry. AMPH outperforms 71.20% of its industry peers.
AMPH has a debt to FCF ratio of 3.51. This is a good value and a sign of high solvency as AMPH would need 3.51 years to pay back of all of its debts.
AMPH has a better Debt to FCF ratio (3.51) than 89.13% of its industry peers.
AMPH has a Debt/Equity ratio of 0.82. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
AMPH's Debt to Equity ratio of 0.82 is on the low side compared to the rest of the industry. AMPH is outperformed by 71.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF 3.51
Altman-Z 2.71
ROIC/WACC1.3
WACC9.59%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.43 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Current ratio of 3.43. This is comparable to the rest of the industry: AMPH outperforms 53.80% of its industry peers.
A Quick Ratio of 2.61 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Quick ratio of 2.61. This is comparable to the rest of the industry: AMPH outperforms 50.54% of its industry peers.
Industry RankSector Rank
Current Ratio 3.43
Quick Ratio 2.61
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.97% over the past year.
The Earnings Per Share has been growing by 61.62% on average over the past years. This is a very strong growth
EPS 1Y (TTM)16.97%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%4.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%4.72%

3.2 Future

The Earnings Per Share is expected to grow by 3.80% on average over the next years.
Based on estimates for the next years, AMPH will show a small growth in Revenue. The Revenue will grow by 6.48% on average per year.
EPS Next Y-3.06%
EPS Next 2Y4.95%
EPS Next 3Y15.2%
EPS Next 5Y3.8%
Revenue Next Year4.27%
Revenue Next 2Y4.79%
Revenue Next 3Y9.78%
Revenue Next 5Y6.48%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 7.13 indicates a rather cheap valuation of AMPH.
Compared to the rest of the industry, the Price/Earnings ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 95.11% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of AMPH to the average of the S&P500 Index (29.75), we can say AMPH is valued rather cheaply.
A Price/Forward Earnings ratio of 7.35 indicates a rather cheap valuation of AMPH.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaply inside the industry as 91.85% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.44, AMPH is valued rather cheaply.
Industry RankSector Rank
PE 7.13
Fwd PE 7.35
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

AMPH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMPH is cheaper than 93.48% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AMPH is valued cheaply inside the industry as 93.48% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 7.78
EV/EBITDA 6.14
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The excellent profitability rating of AMPH may justify a higher PE ratio.
A more expensive valuation may be justified as AMPH's earnings are expected to grow with 15.20% in the coming years.
PEG (NY)N/A
PEG (5Y)0.12
EPS Next 2Y4.95%
EPS Next 3Y15.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (3/3/2025, 5:20:00 PM)

After market: 27.52 0 (0%)

27.52

-0.91 (-3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners74.42%
Inst Owner Change-1.39%
Ins Owners8.05%
Ins Owner Change-0.54%
Market Cap1.32B
Analysts80
Price Target45.14 (64.03%)
Short Float %11.02%
Short Ratio7.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.21%
Min EPS beat(2)-4.74%
Max EPS beat(2)19.17%
EPS beat(4)2
Avg EPS beat(4)3.54%
Min EPS beat(4)-6.79%
Max EPS beat(4)19.17%
EPS beat(8)6
Avg EPS beat(8)24.28%
EPS beat(12)9
Avg EPS beat(12)20.04%
EPS beat(16)12
Avg EPS beat(16)23.91%
Revenue beat(2)1
Avg Revenue beat(2)0.45%
Min Revenue beat(2)-3.71%
Max Revenue beat(2)4.61%
Revenue beat(4)1
Avg Revenue beat(4)-0.7%
Min Revenue beat(4)-3.71%
Max Revenue beat(4)4.61%
Revenue beat(8)5
Avg Revenue beat(8)1.14%
Revenue beat(12)8
Avg Revenue beat(12)1.24%
Revenue beat(16)11
Avg Revenue beat(16)1.83%
PT rev (1m)-20.27%
PT rev (3m)-24.57%
EPS NQ rev (1m)-1.92%
EPS NQ rev (3m)-2.86%
EPS NY rev (1m)-0.48%
EPS NY rev (3m)-0.74%
Revenue NQ rev (1m)-1.7%
Revenue NQ rev (3m)-2.01%
Revenue NY rev (1m)-0.47%
Revenue NY rev (3m)-0.55%
Valuation
Industry RankSector Rank
PE 7.13
Fwd PE 7.35
P/S 1.83
P/FCF 7.78
P/OCF 6.35
P/B 1.82
P/tB 9.96
EV/EBITDA 6.14
EPS(TTM)3.86
EY14.03%
EPS(NY)3.74
Fwd EY13.6%
FCF(TTM)3.54
FCFY12.86%
OCF(TTM)4.33
OCFY15.74%
SpS15.05
BVpS15.13
TBVpS2.76
PEG (NY)N/A
PEG (5Y)0.12
Profitability
Industry RankSector Rank
ROA 10.21%
ROE 21.67%
ROCE 15.46%
ROIC 12.46%
ROICexc 15.2%
ROICexgc 31.92%
OM 29.61%
PM (TTM) 21.8%
GM 52.98%
FCFM 23.52%
ROA(3y)10.22%
ROA(5y)7.84%
ROE(3y)17.58%
ROE(5y)13.18%
ROIC(3y)11.94%
ROIC(5y)N/A
ROICexc(3y)15.69%
ROICexc(5y)N/A
ROICexgc(3y)24.29%
ROICexgc(5y)N/A
ROCE(3y)14.81%
ROCE(5y)N/A
ROICexcg growth 3Y153.1%
ROICexcg growth 5YN/A
ROICexc growth 3Y93.82%
ROICexc growth 5YN/A
OM growth 3Y114.39%
OM growth 5YN/A
PM growth 3Y276.41%
PM growth 5YN/A
GM growth 3Y10.26%
GM growth 5Y8.62%
F-Score8
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF 3.51
Debt/EBITDA 2.21
Cap/Depr 68.92%
Cap/Sales 5.27%
Interest Coverage 7.69
Cash Conversion 77.27%
Profit Quality 107.89%
Current Ratio 3.43
Quick Ratio 2.61
Altman-Z 2.71
F-Score8
WACC9.59%
ROIC/WACC1.3
Cap/Depr(3y)101.15%
Cap/Depr(5y)138.04%
Cap/Sales(3y)5.67%
Cap/Sales(5y)7.92%
Profit Quality(3y)96.84%
Profit Quality(5y)392.61%
High Growth Momentum
Growth
EPS 1Y (TTM)16.97%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%4.55%
EPS Next Y-3.06%
EPS Next 2Y4.95%
EPS Next 3Y15.2%
EPS Next 5Y3.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%4.72%
Revenue Next Year4.27%
Revenue Next 2Y4.79%
Revenue Next 3Y9.78%
Revenue Next 5Y6.48%
EBIT growth 1Y18.5%
EBIT growth 3Y162.82%
EBIT growth 5YN/A
EBIT Next Year31.03%
EBIT Next 3Y13.95%
EBIT Next 5Y22.62%
FCF growth 1Y89.5%
FCF growth 3Y83.79%
FCF growth 5YN/A
OCF growth 1Y82.05%
OCF growth 3Y47.43%
OCF growth 5Y36.88%